Insulet Corporation $PODD Stock Sold by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd lessened its position in shares of Insulet Corporation (NASDAQ:PODD) by 77.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,042 shares of the medical instruments supplier’s stock after selling 6,938 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Insulet were worth $266,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC grew its position in shares of Insulet by 115.6% during the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 104 shares during the last quarter. Activest Wealth Management raised its position in Insulet by 186.3% in the 3rd quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 149 shares during the last quarter. Continuum Advisory LLC purchased a new stake in Insulet in the 2nd quarter valued at $46,000. Sound Income Strategies LLC raised its position in Insulet by 4,620.0% in the 1st quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 231 shares during the last quarter. Finally, State of Wyoming boosted its stake in Insulet by 34.6% during the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after purchasing an additional 73 shares during the period.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $149.01 on Friday. The company has a market cap of $10.33 billion, a P/E ratio of 27.85, a PEG ratio of 1.17 and a beta of 1.11. The company has a 50-day moving average price of $140.58 and a 200 day moving average price of $154.66. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The business had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. During the same period last year, the firm earned $1.17 EPS. The company’s quarterly revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts predict that Insulet Corporation will post 6.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PODD has been the topic of several research reports. TD Cowen lowered their price objective on shares of Insulet from $294.00 to $144.00 and set a “hold” rating on the stock in a research report on Thursday, August 6th. Evercore set a $180.00 price target on Insulet in a research note on Monday, July 6th. Canaccord Genuity Group decreased their price target on Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Insulet in a research report on Monday, September 21st. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $180.00 price objective on shares of Insulet in a research report on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $186.68.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.